Compact Flow Cytometers Automate Labs, Enhance LIS Integration
Flow cytometers are becoming increasingly compact and sophisticated, offering opportunities and challenges for routine clinical use.
Tag: MRD
All
Latest
All
Latest
Why ctDNA Monitoring is Critical in Early Melanoma Recurrence Detection
NeoGenomics' study demonstrates how ctDNA monitoring enables earlier detection of MRD and recurrence risk in high-risk melanoma patients.
All
Latest
Sebia Launches Test for Monitoring Multiple Myeloma Patients
Sebia launched its serum-based minimal residual disease (MRD) test for monitoring in multiple myeloma, M-inSight.
Quest Diagnostics to Acquire Haystack Oncology
After Quest acquires Haystack, Quest expects to adapt the MRD test developed at Haystack as the basis for new clinical lab services.
Read More
Adaptive Biotechnologies Assay Measure’s MRD for Takeda Cancer Treatments
The collaboration will cover programs to aid the development and commercialization of investigational medicines for hematologic malignancies.
Read More
Medicare Extends Coverage of Natera’s Signatera MRD Test to Breast Cancer
Natera’s Signatera MRD test has met coverage requirements for adjuvant and recurrence monitoring in patients with breast cancer.
Read More
C2i Genomics and AzstraZeneca Successfully Evaluate Whole Genome-Based Residual Disease Test for Cancer
C2i Genomics and AstraZeneca collaborated on an evaluation for the potential of whole-genome MRD testing across solid cancers.
Read More
Foresight Diagnostics Patent Issued for Minimal Residual Disease Detection Technology
The USPTO granted Foresight Diagnostics a patent for the detection of MRD using its personalized phased variant detection platform.
Read More
Twist Bioscience’s New Customizable Panels to Advance Minimal Residual Disease Detection
Twist Bioscience launched a custom solution for NGS workflow, offering fully customizable panels to quickly detect minimal residual disease.
Read More
C2i Genomics & Twist Bioscience to Develop Whole-Genome Cancer Detection Materials
The materials will provide labs with the ability to better validate and monitor the quality of their whole-genome cancer screening and MRD products.
Read More
Foresight Diagnostics’ ctDNA Liquid Biopsy Platform Streamlines Treatment of B-Cell Lymphoma
Detection of ctDNA levels with the assay was correlated with detected changes in tumor burden in B-cell lymphoma patients treated with acalabrutinib.
Read More
Foresight Diagnostics Shares Vision of Lymphoma MRD Detection
Foresight’s first commercially available test offering will be a CLIA-validated B-cell lymphoma MRD assay.
Read More
Natera Signatera MRD Test Awarded ADLT Status
The Centers for Medicare & Medicaid Services has granted Advanced Diagnostic Laboratory Test status for the Signatera molecular residual disease test.
Read More
Invitae Opens Early Access to Liquid Biopsy-Based Personalized Cancer Monitoring Test
Full commercial availability of the Invitae liquid biopsy-based PCM as a laboratory-developed test is expected later this year.
Read More
Natera’s Signatera ctDNA Assay Test Receives CE Mark
The Signatera test is a personalized, tumor-informed ctDNA assay optimized for molecular residual disease assessment and treatment monitoring.
Read MoreAdaptive Biotechnologies to Develop Distributable IVD Test Kits for ClonoSEQ and ImmunoSEQ Dx
A partnership with Illumina will enable physicians to order clinical immunodiagnostic tests that can be performed in local laboratories.
Read More